Idioma:

Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction

Nakashima, Mitsutaka ; Miyoshi, Toru ; Ejiri, Kentaro ; Kihara, Hajime ; Hata, Yoshiki ; Nagano, Toshihiko ; Takaishi, Atsushi ; Toda, Hironobu ; Nanba, Seiji ; Nakamura, Yoichi ; Akagi, Satoshi ; Sakuragi, Satoru ; Minagawa, Taro ; Kawai, Yusuke ; Nishii, Nobuhiro ; Fuke, Soichiro ; Yoshikawa, Masaki ; Nakamura, Kazufumi ; Ito, Hiroshi ; Ejiri, Kentaro ; Miyoshi, Toru ; Nakamura, Kazufumi ; Ito, Hiroshi ; Kihara, Hajime ; Hata, Yoshiki ; Nagano, Toshihiko ; Takaishi, Atsushi ; Toda, Hironobu ; Namba, Seiji ; Nakamura, Yoichi ; Akagi, Satoshi ; Sakuragi, Satoru ; Minagawa, Taro ; Kawai, Yusuke ; Nishii, Nobuhiro ; Sato, Tetsuya ; Fuke, Soichiro ; Yoshikawa, Masaki ; Sugiyama, Hiroyasu ; Imai, Michio ; Gotoh, Naoki ; Segawa, Tomonori ; Noda, Toshiyuki ; Koshiji, Masatoshi ; Kajikawa, Yutaka ; Morita, Hiroshi ; Yoshida, Masashi ; Doi, Masayuki ; Oka, Takafumi

ESC Heart Failure, 2022-02, Vol.9 (1), p.712-720 [Periódico revisado por pares]

England: John Wiley & Sons, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction
Autor: Nakashima, Mitsutaka ; Miyoshi, Toru ; Ejiri, Kentaro ; Kihara, Hajime ; Hata, Yoshiki ; Nagano, Toshihiko ; Takaishi, Atsushi ; Toda, Hironobu ; Nanba, Seiji ; Nakamura, Yoichi ; Akagi, Satoshi ; Sakuragi, Satoru ; Minagawa, Taro ; Kawai, Yusuke ; Nishii, Nobuhiro ; Fuke, Soichiro ; Yoshikawa, Masaki ; Nakamura, Kazufumi ; Ito, Hiroshi ; Ejiri, Kentaro ; Miyoshi, Toru ; Nakamura, Kazufumi ; Ito, Hiroshi ; Kihara, Hajime ; Hata, Yoshiki ; Nagano, Toshihiko ; Takaishi, Atsushi ; Toda, Hironobu ; Namba, Seiji ; Nakamura, Yoichi ; Akagi, Satoshi ; Sakuragi, Satoru ; Minagawa, Taro ; Kawai, Yusuke ; Nishii, Nobuhiro ; Sato, Tetsuya ; Fuke, Soichiro ; Yoshikawa, Masaki ; Sugiyama, Hiroyasu ; Imai, Michio ; Gotoh, Naoki ; Segawa, Tomonori ; Noda, Toshiyuki ; Koshiji, Masatoshi ; Kajikawa, Yutaka ; Morita, Hiroshi ; Yoshida, Masashi ; Doi, Masayuki ; Oka, Takafumi
Assuntos: Blood pressure ; Cardiac arrhythmia ; Cardiovascular disease ; Creatinine ; Diabetes ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diuretics ; Ejection fraction ; Enzymes ; Estimated plasma volume ; Glucose ; Heart Failure ; Heart failure with preserved ejection fraction ; Hemoglobin ; Humans ; Laboratories ; Luseogliflozin ; Original ; Patients ; Peptides ; Plasma ; Plasma Volume ; Prospective Studies ; Regression analysis ; Sodium glucose co‐transporter 2 inhibitors ; Sorbitol - analogs & derivatives ; Standard deviation ; Stroke Volume ; Voglibose
É parte de: ESC Heart Failure, 2022-02, Vol.9 (1), p.712-720
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Descrição: Aims Sodium glucose co‐transporter 2 inhibitors have diuretic effects in both patients with glycosuria and with natriuresis. We sought to assess the effect of luseogliflozin on estimated plasma volume (ePV) in patients with type 2 diabetes and heart failure with preserved ejection fraction (HFpEF). Methods and results This study was a post‐hoc analysis of the MUSCAT‐HF trial (UMIN000018395), a multicentre, prospective, open‐label, randomized controlled trial that assessed the effect of 12 weeks of luseogliflozin (2.5 mg, once daily, n = 83) as compared with voglibose (0.2 mg, three times daily, n = 82) on the reduction in brain natriuretic peptide (BNP) in patients with type 2 diabetes and HFpEF. The analysis compared the change in ePV calculated by the Straus formula from baseline to Weeks 4, 12, and 24, using a mixed‐effects model for repeated measures. We also estimated the association between changes in ePV and changes in other clinical parameters, including BNP levels. Luseogliflozin significantly reduced ePV as compared to voglibose at Week 4 {adjusted mean group‐difference −6.43% [95% confidence interval (CI): −9.11 to −3.74]}, at Week 12 [−8.73% (95%CI: −11.40 to −6.05)], and at Week 24 [−11.02% (95%CI: −13.71 to −8.33)]. The effect of luseogliflozin on these parameters was mostly consistent across various patient clinical characteristics. The change in ePV at Week 12 was significantly associated with log‐transformed BNP (r = 0.197, P = 0.015) and left atrial volume index (r = 0.283, P = 0.019). Conclusions Luseogliflozin significantly reduced ePV in patients with type 2 diabetes and HFpEF, as compared with voglibose. The reduction of intravascular volume by luseogliflozin may provide clinical benefits to patients with type 2 diabetes and HFpEF.
Editor: England: John Wiley & Sons, Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction

England: John Wiley & Sons, Inc

Buscando em bases de dados remotas. Favor aguardar.